Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel
Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel is as effective as 400 mg ibuprofen tablets for localised joint pain with a reduced risk of gastrointestinal side effects.2
After topical application it delivers diclofenac directly to the inflamed areas within joint tissues.2 The chemical properties of diclofenac support retention within the joint where it is needed, rather than the blood stream.2,3
Product Information can be found at the bottom of the page
The lowest Number Needed to Treat (NNT) for Voltarol Gels* in a Cochrane Review of topical NSAIDs vs placebo5,6
A Cochrane review of 61 studies (>8000 patients) reported that Voltarol Gels† have the lowest NNT (1.8) of topical NSAIDs in acute musculoskeletal pain, including topicla ibuprofen (3.9).5,6
Find out more about the NNT for Voltarol Gel and what it means for your patients in the short video here.
*1% and 2% Voltarol Gel formulations included in the review.
Low systemic exposure
Reduced risk of systemic side effects vs oral NSAIDs
Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel has a low systemic exposure; approximately 6% is absorbed systemically into the blood, meaning a reduced risk of side effects and drug-drug interactions.7,8 That includes a reduced systemic side-effect risk vs oral NSAIDs (e.g. gastrointestinal events).±9
Recommend Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel for patients with pain associated with osteoarthritis.
Alice has been diagnosed with osteoarthritis of the hand
Alice often suffers joint pain and stiffness but does not want this to control her life or her choices.
She already takes multiple oral medications for other conditions and is concerned about side effects.
She wants to ease the pain and inflammation she suffers in her hands so she can enjoy her life.
Recommend Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel for Alice to offer effective relief of localised joint pain with a reduced risk of systemic side effects.2,9
Recommend Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel for relief of pain and inflammation associated with osteoarthritis.
Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel
For patients with pain associated with osteoarthritis.
Voltarol Back and Muscle Pain Relief 1.16% Gel, Voltarol 12 Hour Joint Pain Relief 2.32% Gel, Voltarol Joint Pain Relief 2.32% Gel, Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel (diclofenac diethylammonium), Voltarol 140 mg Medicated Plaster (diclofenac sodium). Indications Gels: Local symptomatic relief of pain and inflammation in trauma of the tendons, ligaments, muscles and joints e.g. due to sprains, strains and bruises, and localised forms of soft tissue rheumatism. Osteoarthritis Gel only: Relief of pain of non-serious arthritic conditions. Plaster: Local symptomatic, short term treatment of pain in acute strains, sprains or bruises of the extremities following blunt trauma. Dosage and method of use Gels: Adults and children aged 14 years and over. Gently rub 2-4 g into skin of affected site. Gels & Plaster: If symptoms worsen or do not improve within 7 days, seek medical advice. Back and Muscle Gel: Apply 3-4 times daily for up to 7 days. Leave at least 4 hours between applications. No more than 4 applications in 24 hours. Maximum daily dose 16 g. 12 Hour Joint Pain Relief: Apply 2 times daily (morning and evening) for up to 14 days. Maximum daily dose 8 g. Not for use for longer than 14 days unless recommended by doctor. Joint Pain Relief: Apply 2 times daily (morning and evening) for up to 7 days. Maximum daily dose 8 g. Not for use for longer than 7 days unless recommended by doctor. Osteoarthritis Gel: Apply 3-4 times daily for up to 14 days. Maximum daily dose 16 g. Not for use for longer than 14 days unless recommended by doctor. Consult doctor if more than two major joints affected. Plaster: Adults and adolescents aged 16 years and over: Apply 1 plaster to the painful area twice daily (morning and evening), for up to 7 days. Max dose 2 plasters/day. Treat one painful area at a time. Remove prior to bathing/showering. Use for shortest duration necessary to control symptoms. Contraindications Patients whose asthma, angioedema, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs. Hypersensitivity to diclofenac, aspirin, other NSAIDs or excipients. Third trimester of pregnancy. Gels Children under 14 years. Plaster: Children under 16 years. Patients with active peptic ulcer, angioedema, damaged skin. Precautions Gels Do not use on large areas of skin and over a prolonged period. Do not smoke and avoid naked flames. Avoid excessive exposure to sunlight to avoid photosensitivity. Gels/Plaster Apply only to intact, non-diseased skin. Do not use with occlusion. Avoid ingestion or contact with eyes or mucous membranes. Caution in patients with previous or active peptic ulceration; suffering from/previous history of asthma. Discontinue use immediately if skin rash develops. Caution with concomitant use of other diclofenac products or systemic NSAIDs. Plaster: Avoid exposure to ultraviolet light after removing the plaster. Use with caution in elderly patients and in patients with impaired renal, cardiac or hepatic function, bowel disease or haemorrhagic diathesis. Side effects See SPCs for full details. Rash, erythema, pruritus, dermatitis, eczema. Hypersensitivity (including urticaria), angioneurotic oedema. Asthma. Photosensitivity reactions. Gels: Desquamation, skin discolouration. Plaster: application site reactions, dry skin, anaphylactic type reaction. Product licence number, legal category, pack size and RSP (excl. VAT) Back and Muscle Gel: PL 44673/0156 (GSL) 30 g £4.83, 50 g £6.91, 100 g £11.24. 12 Hour Joint Pain Gel: PL 44673/0154 (P), 30 g £6.41, 50 g £9.16, 100 g £15.58. Joint Pain Gel: PL 44673/0160 (GSL), 30 g £6.41, 50 g £9.16. Osteoarthritis Gel: PL 44673/0155 (P), 30 g £4.83, 50 g £6.91, 100 g £11.24. Plaster: PL 44673/0158 (P), 2s £8.25, 5s £15.83. PL holder GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, U.K. Date of preparation May 2020.